there was an overall increase in true lumen diameter and concomitant decrease in false lumen diameter in both acute and nonacute patients at the level of the largest diameter in both the thoracic and abdominal aorta. At 5 years, 66% of acute and 81% of nonacute patients exhibited either a stable or shrinking transaortic diameter in the thoracic aorta; 52% of acute and 24% of nonacute patients experienced growth in transaortic diameter in the abdominal aorta. Five-year freedom from secondary intervention was 66% 6 8% for acute and 71% 6 9% for nonacute patients (log-rank test, P ¼ .71).
Conclusions: Endovascular repair of complicated type B aortic dissection with a composite device design demonstrated low all-cause mortality at 30 days as well as low dissection-related mortality during follow-up. Overall, the acute and nonacute cohorts from the feasibility study appeared to respond similarly to treatment involving use of the stent graft and bare metal stent, demonstrating similar clinical outcomes and favorable aortic remodeling in the thoracic and abdominal aorta. Objective: Carotid artery disease is a major cause of stroke. The in vivo structural features that connote carotid plaque rupture and symptoms remain ill-defined for a given degree of stenosis. We therefore analyzed computed tomography angiography (CTA) images of symptomatic patients enrolled in the Plaques at Risk (PARISK) study designed to determine the natural history of carotid stenosis (30%-70%) causing ipsilateral neurologic events. In each patient, the volume and patterns of calcified and noncalcified plaque components were quantitated in the symptomatic and contralateral asymptomatic carotid bifurcation.
Methods: In 44 consecutive cases, the symptomatic and contralateral asymptomatic carotid bifurcations (n ¼ 88) were subjected to quantitative ImageJ analysis and morphologic grading of plaque volume in 30 to 50 CTA axial slices/bifurcation. Total plaque, calcified and noncalcified plaque components, and percentage calcification volumes were measured. Hounsfield unit (HU) mapping was used to grade maximum calcification arc (400 HU), pattern of calcification (nodular, sheets, adventitial rim), and maximum juxtaluminal dark matter arc (100 HU) representing lipid, hemorrhage, or thrombus. For each bifurcation, North American Symptomatic Carotid Endarterectomy Trial (NASCET) and European Carotid Surgery Trial (ECST) stenosis were determined on CTA. Differences between the symptomatic and asymptomatic sides were analyzed using paired Wilcoxon rank sum.
Results: Percentage stenosis (NASCET, ESCT) was not different between the symptomatic and asymptomatic plaques (14 6 27 vs 7 6 27 [P ¼ .5] and 56 6 16 vs 52 6 16 [P ¼ .3]). There was no correlation between degree of stenosis and total plaque volume for both NASCET (r 2 ¼ 0.05; P ¼ .6) and ECST (r 2 ¼ 0.02; P ¼ .2). Total plaque volume was greater in symptomatic vs asymptomatic plaques (921 6 90 vs 801 6 102; P < .04). Juxtaluminal dark matter was more prevalent in symptomatic plaques (P < .07). Plaques with no dark matter had significantly greater percentage calcification than those with dark matter (P < .002). Overall, there was no difference in percentage calcification volume and calcium patterns between symptomatic and asymptomatic plaques.
Conclusions: In this patient-controlled study, carotid bifurcation plaque volume is greater in symptomatic than in asymptomatic patients with 30% to 70% stenosis. In contrast, degree of stenosis was not related to symptoms or correlated with plaque volume. Juxtaluminal dark matter, a surrogate for soft plaque, is more prevalent in symptomatic plaques and is associated with reduced calcification volume. However, plaque calcification volume and calcium morphologic patterns did not differ between symptomatic and asymptomatic plaques. Trials investigating the natural history of carotid disease should consider assessment of carotid plaque structural components and their transmural spatial distribution rather than relying solely on the degree of stenosis.
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VESS10. Natural History of Target Vessel Endoleaks After Fenestrated-Branched Endovascular Aortic Repair
Akhilesh K. Jain, Gustavo S. Oderich, Emanuel R. Tenorio, Jussi M. Karkkainen, Bernardo C. Mendes, Thanila A. Macedo, Terri J. Vrtiska, Peter Gloviczki. Mayo Clinic, Rochester, Minn
Objective: The objective of this study was to analyze the natural history of target vessel endoleaks detected by predismissal computed tomography angiography (CTA) after fenestrated-branched endovascular aneurysm repair (F-BEVAR) for pararenal aneurysms or thoracoabdominal aortic aneurysms (TAAAs).
Methods: We reviewed the clinical data and imaging of consecutive patients treated by F-BEVAR between 2007 and 2017. Target vessel endoleak due to insufficient attachment (type IIIC), stent fracture/tear (type IIID), or inadequate seal (type IC) was identified by predismissal CTA (Fig) . Follow-up included clinical examination, CTA, and renal-mesenteric duplex ultrasound (DUS) at 2 months, 6 months, and annually thereafter. End points were resolution or persistence of target vessel endoleak, sac enlargement (>5 mm), device migration (>10 mm), aneurysm rupture, and secondary interventions.
Results: There were 386 patients (289 male; mean age, 7567.7 years) treated by F-BEVAR for 196 pararenal aneurysms and 190 TAAAs. A total of 1350 renal-mesenteric arteries were targeted by 1027 fenestrations, 228 directional branches, and 95 scallops with a mean of 3.4 6 0.9 vessels per patient. Predismissal CTA identified any endoleak in 139 patients (36%): type II in 111 patients (29%), type III in 30 (8%), type I in 8 (2%), and indeterminate in 12 (3%). Thirty-six patients (9%) had target vessel endoleaks, including 30 type IIIC, 3 type IIID, and 3 type IC. Incidence of 
